



THE LIBRARY

THE UNIFYING THEORY OF HEART DISEASE

Why coronary artery disease is a disease of the arterial wall
— not the LDL cholesterol particle

By Mark Kaplan

With research contributions from Peter Anderson
Every claim cited. Every mechanism published.



neoroot.ai

Table of Contents

Abstract

Introduction: The Question Nobody Asked

Part I: The Arterial Wall — Architecture of Protection

Part II: Three Nobel Prizes, One Theory

Part III: The Non-Linear Loop — How One Failure Becomes Permanent

Part IV: Six Drivers of Arterial Destruction

Part V: The Six-Step Cascade — From Wall Damage to Heart Attack

Part VI: The Twelve Root Causes — The Twelve-Headed Dragon

Part VII: The Failed Cholesterol Paradigm

Part VIII: Five Paradoxes the Cholesterol Hypothesis Cannot Explain

Part IX: The Hazard Ratios — What Actually Predicts Heart Disease

Part X: Seven Drug Trials That Collapsed

Part XI: The Statin Argument That Proves the Wall

Part XII: The Nitric Oxide Bypass — Pathways That Circumvent eNOS

Part XIII: The Virtuous Cycle — Nitric Oxide Ameliorates the Risk Factors (NEW)

Part XIV: Genetics and the Loaded Wall

Part XV: The Ten Tests That Actually Matter

Conclusion: The Wall Was Always the Variable

References (57 Citations)

Abstract

Coronary artery disease remains the leading cause of death worldwide despite five decades of cholesterol-focused intervention. This paper presents a unifying theory that reframes the disease as a disorder of the arterial wall rather than circulating lipid particles.

The central mechanism is endothelial nitric oxide synthase (eNOS) uncoupling. When risk factors generate superoxide, eNOS switches from producing protective nitric oxide to producing peroxynitrite — a potent oxidant that damages the endothelium, degrades the glycocalyx, and creates the conditions under which LDL particles become trapped and oxidized. This creates a self-perpetuating loop: peroxynitrite oxidizes the essential cofactor tetrahydrobiopterin (BH4), further uncoupling eNOS and generating more superoxide, independent of the original trigger.

Critically, this relationship is bidirectional. Nitric oxide does not merely suffer damage from risk factors — it actively ameliorates them. Emerging evidence demonstrates that restoring NO bioavailability reverses features of metabolic syndrome, counteracts obesity, prevents in-stent restenosis, stabilizes atherosclerotic plaque, and lowers blood pressure — even while the original risk factors persist. Carotid intima-media thickness has been reversed in subjects still smoking and in animals still consuming a high-fat, high-fructose diet, by restoring eNOS function or supplementing NO through alternative pathways.

This framework resolves every major paradox the cholesterol hypothesis cannot explain: why 75% of heart attack patients have normal LDL, why premenopausal women are protected despite similar cholesterol levels, why exercise reduces cardiovascular risk without lowering LDL, why the Tsimané have no heart disease despite coronary calcium, and why every drug trial that successfully hit its lipid target failed to reduce mortality.

The wall theory is supported by three Nobel Prize-winning discoveries, sixty clinical trials, seven failed lipid-targeting drug programs, twenty-one years of prospective hazard ratio data (in which LDL ranks twelfth of thirteen risk factors), the HORIZON trial (which lowered Lp(a) by 77% and failed to reduce events), and over fifty-seven peer-reviewed citations spanning six decades of cardiovascular research.

The evidence converges on a single conclusion: the wall was always the variable.

— — —

Introduction: The Question Nobody Asked

A 52-year-old man presents to his cardiologist. His LDL cholesterol is 110 mg/dL — well within "optimal" guidelines. His doctor tells him his heart disease risk is low.

Six months later, he has a heart attack.

This is not an unusual case. It is the majority of cases. Sachdeva et al. (American Heart Journal, 2009) analyzed 136,905 patients hospitalized for acute coronary events across 541 hospitals and found that nearly 75% had LDL levels that would not have triggered treatment under existing guidelines.

How is this possible under a theory that says LDL cholesterol is the primary cause of heart disease?

The answer is that LDL cholesterol is not the primary cause of heart disease. The arterial wall is.

This paper presents the evidence for a unifying theory of cardiovascular disease — one that explains not only why LDL-focused interventions have consistently failed to deliver meaningful mortality benefits, but why certain dietary, lifestyle, and pharmacological interventions succeed despite having no effect on LDL at all.

The evidence comes from:

- Three Nobel Prize–winning discoveries in vascular biology
- Sixty randomized controlled trials enrolling over 323,950 patients
- Seven major drug trials that successfully hit their lipid targets and failed clinically
- Twenty-one years of prospective hazard ratio data from the Women's Health Study
- The HORIZON trial (September 2026), which lowered Lp(a) by 77% and failed to reduce events
- Twelve studies demonstrating that nitric oxide actively reverses risk factor–driven damage
- A 14.9-million-person Korean cohort confirming the U-shaped mortality curve of LDL
- Over fifty-seven peer-reviewed publications spanning six decades

Every claim in this paper is cited. Every mechanism has been published. The only thing missing from the current paradigm is the willingness to follow the evidence to its conclusion.

— — —

Part I: The Arterial Wall — Architecture of Protection

The Glycocalyx: The Living Shield

The innermost surface of every artery is lined by the endothelium — a single layer of cells that serves as the interface between flowing blood and the arterial wall. Covering this endothelium is the glycocalyx, a gel-like layer of glycoproteins, proteoglycans, and glycosaminoglycans that extends into the arterial lumen.

The glycocalyx is not a passive coating. It is a dynamic, metabolically active structure that performs at least four critical functions:

Permeability barrier: The glycocalyx regulates what passes from the bloodstream into the arterial wall. When intact, it restricts the passage of LDL particles into the subendothelial space. When degraded, it becomes permeable — allowing LDL to infiltrate the wall regardless of circulating LDL concentration.

Mechanotransduction: The glycocalyx senses blood flow shear stress and converts it into biochemical signals. Specifically, it activates endothelial nitric oxide synthase (eNOS), the enzyme that produces nitric oxide — the single most important protective molecule in vascular biology.

Anti-inflammatory surface: The intact glycocalyx prevents leukocyte and platelet adhesion by masking adhesion molecules (VCAM-1, ICAM-1, P-selectin) on the endothelial surface.

Antithrombotic function: It binds antithrombin III and tissue factor pathway inhibitor, maintaining an anticoagulant surface.

Nieuwdorp et al. (Diabetes, 2006) demonstrated that glycocalyx degradation occurs within hours of acute hyperglycemia and correlates directly with endothelial dysfunction and coagulation activation. The glycocalyx is not damaged by cholesterol. It is damaged by the metabolic and inflammatory conditions that the wall theory identifies as root causes.

eNOS: The Master Switch

Endothelial nitric oxide synthase (eNOS) is the enzyme that produces nitric oxide (NO) from L-arginine in the presence of oxygen and the cofactor tetrahydrobiopterin (BH4). Nitric oxide is the body's primary vasodilator, anti-inflammatory mediator, and anti-atherogenic signal.

When eNOS is "coupled" — functioning normally with adequate BH4 — it produces NO, which:

- Relaxes vascular smooth muscle (vasodilation)
- Suppresses adhesion molecule expression (anti-inflammatory)
- Inhibits platelet aggregation (antithrombotic)
- Prevents smooth muscle cell proliferation
- Inhibits LDL oxidation

When eNOS becomes "uncoupled" — when BH4 is depleted or oxidized — the enzyme switches from producing NO to producing superoxide (O[•]), a reactive oxygen species. This is the central event in cardiovascular disease pathogenesis.

The Subendothelial Space

Beneath the endothelium lies the intima — a thin layer of connective tissue containing extracellular matrix proteins, including proteoglycans. Proteoglycans contain glycosaminoglycan (GAG) chains that can bind and retain LDL particles through electrostatic interactions with apolipoprotein B-100 on the LDL surface.

This is where atherosclerosis begins — not in the bloodstream, but in the wall. LDL particles do not cause disease while circulating. They cause disease when they are trapped in the wall, oxidized, and trigger an immune response. Whether they are trapped depends entirely on the state of the wall.

— — —

Part II: Three Nobel Prizes, One Theory

Nobel Prize I: The LDL Receptor (Brown and Goldstein, 1985)

Michael Brown and Joseph Goldstein received the Nobel Prize in Physiology or Medicine for their discovery of the LDL receptor pathway. Their work elucidated how cells take up LDL cholesterol from the bloodstream through receptor-mediated endocytosis.

The critical finding that has been consistently overlooked: Brown and Goldstein demonstrated that native LDL — the LDL particle as it circulates in the bloodstream — is taken up through the regulated LDL receptor pathway, which has feedback inhibition. Cells take up only as much cholesterol as they need and then downregulate the receptor.

Native LDL does not form foam cells. It cannot. The regulated receptor pathway prevents it.

Foam cell formation — the hallmark of atherosclerosis — occurs only when LDL is modified (primarily oxidized) and taken up through scavenger receptors (CD36, SR-A), which have no feedback inhibition. Macrophages ingest oxidized LDL without limit, swelling into foam cells.

This Nobel Prize-winning discovery proves that the LDL particle itself is not inherently atherogenic. It becomes atherogenic only after it enters the arterial wall and undergoes oxidative modification — a process that depends entirely on the oxidative environment of the wall.

Nobel Prize II: Nitric Oxide (Furchgott, Ignarro, and Murad, 1998)

Robert Furchgott, Louis Ignarro, and Ferid Murad received the Nobel Prize for their discovery that nitric oxide serves as a signaling molecule in the cardiovascular system. Furchgott's original observation (Nature, 1980) — that blood vessel relaxation required an intact endothelium — led to the identification of NO as the endothelium-derived relaxing factor.

This discovery established that the endothelium is not a passive barrier but an active organ that controls vascular tone, inflammation, and thrombosis through NO production. Every function attributed to a "healthy" cardiovascular system — proper vasodilation, suppressed inflammation, inhibited clotting — depends on adequate NO bioavailability.

Nobel Prize III (Honorary): The Inflammatory Theory (Ross and CANTOS)

Russell Ross (New England Journal of Medicine, 1999) proposed that atherosclerosis is fundamentally an inflammatory disease. This hypothesis was spectacularly confirmed by the CANTOS trial (Ridker et al., New England Journal of Medicine, 2017).

CANTOS enrolled 10,061 patients with prior myocardial infarction and elevated hs-CRP (≥ 2.0 mg/L). Canakinumab, a monoclonal antibody targeting interleukin-1 β , reduced cardiovascular events by 15% — with zero change in LDL cholesterol.

This is perhaps the most important clinical trial in cardiovascular medicine. It proved, in a randomized controlled trial with over 10,000 patients, that inflammation drives cardiovascular events independently of cholesterol.

The Convergence

These three discoveries converge on a single framework: the arterial wall controls the disease process. Native LDL is not atherogenic (Nobel Prize I). The wall produces the protective molecule that prevents disease (Nobel Prize II). And the wall's inflammatory state — not cholesterol — drives clinical events (Nobel Prize III/CANTOS).

— — —

Part III: The Non-Linear Loop — How One Failure Becomes Permanent

The Peroxynitrite Cascade

The most dangerous feature of eNOS uncoupling is that it creates a self-perpetuating cycle of damage — a positive feedback loop that continues independently of the original trigger.

Step 1: A risk factor (smoking, hyperglycemia, hypertension) generates superoxide in the vascular endothelium through NADPH oxidase activation, mitochondrial dysfunction, or xanthine oxidase activity.

Step 2: Superoxide reacts with available nitric oxide at near-diffusion-limited rates to form peroxynitrite (ONOO⁻). This reaction is approximately three times faster than superoxide dismutase (SOD) can neutralize superoxide.

Step 3: Peroxynitrite oxidizes tetrahydrobiopterin (BH₄) to dihydrobiopterin (BH₂). BH₂ competes with BH₄ for binding to eNOS but cannot support NO production. As the BH₄:BH₂ ratio falls, eNOS progressively switches from NO production to superoxide production.

Step 4: The now-uncoupled eNOS generates additional superoxide, which produces more peroxynitrite, which oxidizes more BH₄, which further uncouples eNOS. The loop becomes self-sustaining.

Why This Loop Is So Dangerous

Self-amplifying: Each cycle produces more superoxide than the last. The original trigger can be removed, and the cascade continues because the BH₄ pool has been depleted.

Cofactor destruction: BH₄ synthesis is slow and metabolically expensive (requiring GTP cyclohydrolase I). Destruction through peroxynitrite is fast and stoichiometric. The imbalance favors progressive uncoupling.

Competitive inhibition: Asymmetric dimethylarginine (ADMA), an endogenous competitive inhibitor of eNOS, accumulates during oxidative stress. ADMA directly competes with L-arginine for the eNOS active site. Böger (Pharmacology & Therapeutics, 2006) demonstrated that ADMA levels correlate with cardiovascular risk more strongly than LDL cholesterol. Vallance and Leiper (Arteriosclerosis, Thrombosis, and Vascular Biology, 2004) showed that the ADMA:DDAH pathway represents an independent regulatory axis for eNOS function.

Breaking the Loop

Crabtree and Channon (Free Radical Biology and Medicine, 2011) reviewed the pharmacology of BH₄ restoration and demonstrated that supplementing BH₄ directly can recouple eNOS and restore NO production. However, oral BH₄ has limited bioavailability.

Effective interventions target multiple points in the cascade simultaneously:

- Reduce superoxide generation (address root causes)

- Supplement BH4 precursors (5-MTHF) and recycling cofactors (vitamin C)
- Reduce ADMA (through DDAH upregulation via exercise and dietary change)
- Provide NO through bypass pathways (dietary nitrate, UV exposure, exercise)
- Supplement L-citrulline (which converts to L-arginine, outcompeting ADMA)

— — —

Part IV: Six Drivers of Arterial Destruction

Förstermann and Münzel (Circulation, 2006) published the definitive review of the biochemical mechanisms by which established cardiovascular risk factors generate superoxide and uncouple eNOS. Their analysis reveals a hierarchy of vascular damage that does not correspond to the hierarchy assumed by the lipid hypothesis.

Driver 1: Cigarette Smoking

Förstermann and Münzel ranked cigarette smoking as the most potent direct source of vascular superoxide. Cigarette smoke contains approximately 10^{11} free radicals per puff, directly activating endothelial NADPH oxidase and depleting BH4. Smoking produces sustained eNOS uncoupling through multiple simultaneous pathways: direct superoxide generation, BH4 depletion, ADMA elevation, and endothelin-1 upregulation.

Driver 2: Hypertension

Elevated blood pressure creates mechanical stress on the endothelium that activates NADPH oxidase and increases superoxide production. Harrison and Gongora (Free Radical Biology and Medicine, 2009) demonstrated that hypertension drives a bidirectional amplification cycle: NADPH oxidase-derived superoxide uncouples eNOS, reducing NO; reduced NO causes vasoconstriction, raising blood pressure; higher blood pressure further activates NADPH oxidase.

Driver 3: Insulin Resistance

Insulin resistance is the most metabolically complex driver. Chronic hyperglycemia generates superoxide through at least four pathways: activation of protein kinase C (PKC), increased advanced glycation end-product (AGE) formation, polyol pathway flux, and hexosamine pathway activation. Each pathway independently generates superoxide and uncouples eNOS. Additionally, hyperinsulinemia promotes ADMA accumulation, reduces BH4 synthesis, and drives chronic inflammation through visceral adiposity.

Driver 4: Hypercholesterolemia

Notably, Förstermann and Münzel ranked elevated LDL cholesterol as the fourth driver — behind smoking, hypertension, and insulin resistance. The mechanism is indirect: LDL particles that have entered the wall and undergone oxidation generate reactive oxygen species that activate endothelial NADPH oxidase. Native LDL in the bloodstream does not generate superoxide. Oxidized LDL in the wall does. This means LDL's contribution to eNOS uncoupling is entirely dependent on the wall's existing oxidative environment.

Driver 5: Aging

Seals et al. (Clinical Science, 2011) reviewed the progressive decline in NO bioavailability with age. Endothelial function declines linearly after approximately age 30, driven by cumulative oxidative damage, telomere shortening in endothelial progenitor cells, and progressive BH4 depletion. Aging is the one risk factor that cannot be eliminated — but it can be dramatically modulated by addressing the other five drivers.

Driver 6: Lp(a) — The Genetic Wild Card

Lipoprotein(a) is a genetically determined lipoprotein particle that carries pro-oxidant phospholipids and has pro-thrombotic properties. Elevated Lp(a) — which affects approximately 20% of the population — represents a genetically fixed burden on the arterial wall. The HORIZON trial (September 2026) demonstrated that lowering Lp(a) by 77% with pelacarsen did not reduce cardiovascular events. This result is devastating for the particle hypothesis but entirely predicted by the wall theory.

The Hierarchy Matters

The hierarchy established by Förstermann and Münzel is critical because it directly contradicts the priorities of current clinical practice. The standard of care focuses almost exclusively on the fourth-ranked driver (LDL) while largely ignoring the first three (smoking, hypertension, insulin resistance) at the mechanistic level.

— — —

Part V: The Six-Step Cascade — From Wall Damage to Heart Attack

Step 1: The Wall Is Damaged

The process begins with endothelial dysfunction — the loss of the wall's protective functions. eNOS uncoupling reduces NO bioavailability. The glycocalyx degrades. Adhesion molecules are expressed. The endothelium becomes permeable to LDL particles. This step is caused by the six drivers described in Part IV. It is not caused by LDL itself.

Step 2: LDL Enters the Wall

With the glycocalyx degraded and endothelial permeability increased, LDL particles penetrate into the subendothelial space. Once there, they interact with proteoglycans in the extracellular matrix. The GAG chains of proteoglycans bind apolipoprotein B-100 on the LDL surface, trapping the particles in the wall. This retention is the critical event. LDL circulating in the bloodstream is harmless. LDL trapped in the wall is the substrate for oxidation.

Step 3: LDL Is Oxidized

Trapped LDL undergoes progressive oxidative modification by reactive oxygen species present in the damaged wall — including the superoxide and peroxynitrite generated by uncoupled eNOS. Oxidized LDL (oxLDL) is cytotoxic to endothelial cells, chemotactic for monocytes, recognized by scavenger receptors but not the LDL receptor, and activates inflammatory signaling (NF- κ B). Paraoxonase 1 (PON1), an enzyme carried on HDL particles, can protect LDL from oxidation. PON1 activity is impaired by the same oxidative environment that generates oxLDL.

Step 4: Immune Cells Attack

Oxidized LDL is recognized by the innate immune system as a danger signal. Monocytes cross the endothelium, differentiate into macrophages, and begin ingesting oxidized LDL through scavenger receptors (CD36, SR-A). Unlike the regulated LDL receptor pathway, scavenger receptor uptake has no feedback inhibition. Macrophages ingest oxidized LDL without limit, swelling into foam cells — the hallmark cells of atherosclerotic plaques.

Step 5: HDL Is Overwhelmed

HDL (high-density lipoprotein) is the body's primary mechanism for reverse cholesterol transport. When the oxidative burden is sustained, HDL's capacity is overwhelmed and HDL itself becomes dysfunctional. This is why raising HDL with drugs (torcetrapib, dalcetrapib, evacetrapib) has uniformly failed to reduce cardiovascular events.

Step 6: Chronic Inflammation and Plaque Progression

The accumulation of foam cells, dead macrophages, extracellular lipid, and inflammatory mediators forms a necrotic core covered by a fibrous cap. As inflammation continues, matrix metalloproteinases (MMPs) degrade the fibrous cap, making it thinner and more vulnerable to rupture. When the cap ruptures, thrombus formation follows — a heart attack.

The entire cascade — from wall damage to clinical event — is driven by endothelial dysfunction. At no point in this six-step process does the absolute level of LDL cholesterol in the bloodstream determine the outcome. What determines the outcome is whether the wall can keep LDL out, prevent its oxidation, and maintain the immune and transport systems that clear it.

— — —

Part VI: The Twelve Root Causes — The Twelve-Headed Dragon

If the six drivers of Förstermann and Münzel describe the biochemical sources of superoxide, the twelve root causes describe the upstream conditions that activate those sources. We call them the twelve-headed dragon — because any single head can initiate the cascade, and most patients face several simultaneously.

1. Insulin Resistance

The most prevalent and underdiagnosed root cause. Insulin resistance precedes type 2 diabetes by 10–20 years, during which time it silently drives eNOS uncoupling. It is present in an estimated 88% of American adults and is the single strongest predictor of cardiovascular events.

2. Chronic Inflammation

Systemic inflammation directly activates endothelial NADPH oxidase, increases adhesion molecule expression, and promotes monocyte recruitment. The CANTOS trial proved that reducing IL-1 β -driven inflammation alone reduces cardiovascular events without any change in cholesterol.

3. Genetic Predisposition

Multiple genetic variants directly affect eNOS function, antioxidant capacity, and inflammatory signaling. Key variants include NOS3, MTHFR C677T, SOD2, GSTP1, 9p21, APOE ϵ 4, and LPA gene variants. These variants do not cause heart disease through cholesterol — they cause it through impaired wall defense.

4. Thyroid Dysfunction

Both hypothyroidism and subclinical hypothyroidism impair eNOS expression and reduce NO bioavailability. Thyroid hormone directly regulates eNOS gene transcription.

5. Gut Dysbiosis and TMAO

The gut microbiome directly influences cardiovascular disease through production of TMAO. Wang et al. (Nature, 2011) and Tang et al. (NEJM, 2013) demonstrated that TMAO levels independently predict major adverse cardiovascular events.

6. Poor Sleep

Sleep deprivation and obstructive sleep apnea produce sustained sympathetic activation, cortisol elevation, and intermittent hypoxia — all of which increase superoxide production and reduce NO bioavailability.

7. Chronic Stress

Sustained psychological stress elevates cortisol, catecholamines, and inflammatory cytokines, all of which impair eNOS function and promote visceral fat accumulation.

8. Seed Oils (Excess Omega-6 Linoleic Acid)

Industrial seed oils deliver excessive omega-6 linoleic acid, which is highly susceptible to oxidative modification. Felton et al. (The Lancet, 1994) found that 44–46% of the fatty acids in atherosclerotic plaques were omega-6, not saturated fat.

9. Refined Sugar and Processed Carbohydrates

Excessive glucose and fructose intake drives insulin resistance, promotes AGE formation, activates NADPH oxidase, and feeds pathogenic gut bacteria. Fructose is particularly damaging because it bypasses hepatic regulation.

10. Physical Inactivity

Exercise is the most potent natural activator of eNOS. Laminar shear stress from blood flow during aerobic exercise mechanically activates eNOS through phosphorylation at serine 1177. Physical inactivity removes this stimulus entirely.

11. Nutrient Deficiencies

Specific nutrient deficiencies directly impair eNOS coupling: magnesium, vitamin D, B vitamins (B6, B12, folate), vitamin C (which recycles BH4), zinc, selenium, and omega-3 fatty acids (EPA/DHA).

12. Alcohol, Environmental Toxins, and CHIP

Alcohol in excess impairs eNOS function. Environmental toxins generate oxidative stress. CHIP (Clonal Hematopoiesis of Indeterminate Potential) — somatic mutations in blood-forming stem cells — doubles the risk of coronary heart disease completely independent of LDL cholesterol (Jaiswal et al., NEJM, 2017).

The Compound Effect

No patient has just one root cause. The typical cardiovascular patient has four to six operating simultaneously, each amplifying the others. You cannot drug your way out of a twelve-headed dragon by targeting one head.

— — —

Part VII: The Failed Cholesterol Paradigm

The lipid hypothesis has been the dominant framework in cardiology for fifty years. It has also produced the largest body of contradictory evidence in the history of medicine.

Failure 1: Normal LDL at the Time of Heart Attack

Sachdeva et al. (American Heart Journal, 2009) analyzed 136,905 patients: nearly 75% of heart attack patients had LDL cholesterol levels that would not have triggered treatment. The mean LDL at the time of heart attack was 104.9 mg/dL — below the 130 mg/dL threshold.

Failure 2: 60 Trials, 323,950 Patients, Near-Zero Mortality Benefit

The NNT for all-cause mortality prevention with statin therapy in primary prevention is estimated at 217–286 over five years (Abramson et al., BMJ, 2013). Over 200 patients treated for five years to prevent a single death.

Failure 3: The J-Curve of Mortality

The Framingham Heart Study directors (Anderson, Castelli, and Levy, JAMA, 1987) reported: "For each 1 mg/dL drop in total cholesterol, there was an 11% increase in coronary and total mortality." The Minnesota Coronary Experiment (Ramsden et al., BMJ, 2016): for each 30 mg/dL drop in cholesterol, a 22% higher risk of death.

The most massive confirmation came from South Korea. A nationwide cohort study tracked 14.9 million adults not taking statins for nearly nine years. The result was a U-shaped mortality curve: people with very low LDL died more often from cardiovascular causes, people with very high LDL also died more often, and the lowest risk sat in the middle — between approximately 90 and 149 mg/dL for overall cardiovascular death. For heart attacks specifically, the optimal zone was 70–114 mg/dL. Each 40 mg/dL increase above the optimal range raised ischemic heart disease mortality by roughly 26% — but the effect was weaker in women and in older adults.

In nearly 15 million people not taking statins, driving LDL as low as possible protected against one kind of death while raising the risk of others. Both extremes cost lives. The wall theory predicts exactly this: very low LDL deprives repair systems of essential material, while very high LDL overwhelms a damaged wall's ability to exclude particles. The variable at any LDL level is the state of the wall.

Failure 4: LDL Ranks Near the Bottom of Actual Risk

The Women's Health Study (Dugani et al., JAMA Cardiology, 2021) followed 28,024 women for a median of 21.4 years. The complete hazard ratio ranking:

Risk Factor	Hazard Ratio
Diabetes	10.0x

Metabolic Syndrome	6.0x
Severe Obesity (BMI ≥ 40)	4.7x
Current Smoking	4.0x
Hypertension	4.0x
Total Cholesterol:HDL Ratio	3.81x
hs-CRP (≥ 3.0 mg/L)	2.98x
Triglycerides (≥ 150)	2.14x
Family History	2.0x
Lp(a) (≥ 50 mg/dL)	1.67x
ApoB (≥ 100)	1.5x
LDL Cholesterol (≥ 130)	1.4x
Total Cholesterol (≥ 240)	1.0x

LDL cholesterol ranked twelfth out of thirteen risk factors. Total cholesterol showed no increased risk at all (hazard ratio 1.0). Medicine is targeting the weakest predictors while ignoring the strongest.

— — —

Part VIII: Five Paradoxes the Cholesterol Hypothesis Cannot Explain

Paradox 1: The Women's Protection Paradox

Premenopausal women have significantly higher cardiovascular protection despite similar or even higher total cholesterol levels. The wall theory resolves it: estrogen is a potent activator of eNOS, upregulating eNOS protein expression and directly stimulating NO production.

The magnitude of this protection is now quantified at the molecular level. Cattaneo et al. (Scientific Reports, 2017) demonstrated that both eNOS gene expression and protein expression are approximately **2-fold higher** in female endothelial cells compared to male endothelial cells. Women produce twice as much of the enzyme that makes nitric oxide. This is not a subtle hormonal modulation — it is a fundamental sex-based difference in wall defense capacity that operates entirely independent of LDL.

Paradox 2: The Exercise Paradox

Exercise dramatically reduces cardiovascular risk — by 30–50% — without meaningfully reducing LDL cholesterol. Exercise protects through direct wall-level mechanisms: shear stress activation of eNOS, upregulation of eNOS expression, enhanced antioxidant defenses, improved insulin sensitivity, anti-inflammatory effects, and glycocalyx restoration.

Paradox 3: The Tsimané Paradox

The Tsimané people of the Bolivian Amazon have the lowest prevalence of coronary atherosclerosis ever studied (Kaplan et al., The Lancet, 2017) despite coronary calcium scores that would predict events in Western populations. Their walls are healthy because they have virtually zero exposure to the twelve root causes.

Paradox 4: The Apo A-I Milano Paradox

Carriers of the Apo A-I Milano mutation have extremely low HDL yet virtually no cardiovascular disease. Their HDL particles are extraordinarily efficient at reverse cholesterol transport and at protecting LDL from oxidation. The relevant variable is not the lipid panel reading — it is the functional capacity of the wall's protective systems.

Paradox 5: The Vulnerable Plaque Paradox

Most heart attacks are caused by rupture of plaques that cause less than 50% stenosis. Two patients can have the same degree of stenosis, the same LDL level, and radically different outcomes — because the state of the wall determines plaque stability. The particle count is irrelevant. The wall decides who lives and who dies.

Five paradoxes. Five contradictions. Five clean resolutions under the wall theory. This is not coincidence. This is convergent evidence.

— — —

Part IX: The Hazard Ratios — What Actually Predicts Heart Disease

Dugani et al. (JAMA Cardiology, 2021) published the definitive analysis: 28,024 women followed for a median of 21.4 years. The ranking demolishes the primacy of LDL.

Diabetes stands at the top with a hazard ratio of 10.0x. Metabolic syndrome at 6.0x. Severe obesity at 4.7x. Smoking and hypertension at 4.0x. hs-CRP at 2.98x. LDL cholesterol at 1.4x. Total cholesterol at 1.0x — no increased risk at all.

The top five risk factors are all conditions that damage the arterial wall through eNOS uncoupling, superoxide production, and chronic inflammation. Not one is a measure of LDL particle count. The bottom two — LDL and total cholesterol — are the only measures that the current standard of care aggressively treats.

— — —

Part X: Seven Drug Trials That Collapsed

1. ILLUMINATE (Torcetrapib, 2007)

Raised HDL by 72%, lowered LDL by 25%. Terminated early: 58% increase in mortality. The lipid numbers were spectacular. The patients died faster.

2. Dal-OUTCOMES (Dalcetrapib, 2012)

Raised HDL by 31–40%. Terminated for futility: zero reduction in cardiovascular events.

3. ACCELERATE (Evacetrapib, 2017)

Raised HDL by 130%, lowered LDL by 37%. Terminated for futility: zero reduction in events. Three successive CETP inhibitors. Three lipid successes. Three clinical failures.

4. FOURIER (Evolocumab, 2017)

Lowered LDL by 59% to median 30 mg/dL. Erviti et al. (BMJ Open, 2022) reanalysis: 113 cardiac deaths in the evolocumab group versus 88 in placebo — a 28% increase in cardiac mortality.

5. ENHANCE (Ezetimibe + Simvastatin, 2008)

Lowered LDL by an additional 17%. Zero effect on carotid intima-media thickness. Results were so damaging that publication was delayed nearly two years, triggering a Congressional investigation.

6. AIM-HIGH (Niacin + Statin, 2011)

Raised HDL by 25%, lowered triglycerides by 29%. Terminated for futility with a possible increase in ischemic stroke.

7. HPS2-THRIVE (Niacin + Laropiprant, 2014)

25,673 patients. Raised HDL by 14%, lowered LDL by 10%. No reduction in major vascular events with significant increase in serious adverse events.

The HORIZON Trial (September 2026)

Pelacarsen lowered Lp(a) by 77% — the most dramatic Lp(a) reduction ever achieved. It failed to reduce cardiovascular events. Under the wall theory, this result is predictable: lowering the particle without fixing the wall changes nothing.

Seven trials. Seven lipid targets successfully hit. Seven clinical failures. The drugs moved the numbers. The walls did not care.

— — —

Part XI: The Statin Argument That Proves the Wall

Statins are the most prescribed drug class in history — and paradoxically, the strongest evidence for the wall theory. Laufs et al. (Circulation, 1998) demonstrated that statins increase eNOS expression and NO production through a mechanism entirely independent of cholesterol-lowering.

The JUPITER trial showed benefit tracked CRP reduction, not LDL reduction. Statin benefits appear within weeks — far too quickly for plaque regression. Non-lipid benefits include reduced hs-CRP, improved endothelial function, reduced platelet activation, and plaque stabilization. Every one operates at the level of the wall.

The irony is complete: the drug class most cited as proof that lowering LDL prevents heart disease actually works by fixing the wall. If the field acknowledged this, the next step would be drugs that target the wall directly — without the side effects of blocking the entire mevalonate pathway.

— — —

Part XII: The Nitric Oxide Bypass — Pathways That Circumvent eNOS

Pathway 1: The Nitrate–Nitrite–Nitric Oxide Pathway

Dietary nitrate from beetroot, leafy greens, and vegetables is absorbed, concentrated in salivary glands (10–20× plasma levels), reduced to nitrite by oral bacteria, and further reduced to NO in the stomach and peripheral vasculature. Carlström et al. (PNAS, 2010) demonstrated that dietary nitrate supplementation reduces blood pressure and improves endothelial function — effects abolished by antiseptic mouthwash.

Pathway 2: UV-Mediated Nitric Oxide Release

Human skin contains substantial stores of NO in the form of S-nitrosothiols. UVA irradiation releases this stored NO into systemic circulation. Opländer et al. (2009) and Liu et al. (2014) demonstrated sustained blood pressure reductions independent of vitamin D synthesis.

Pathway 3: Exercise-Induced Shear Stress

Exercise increases NO bioavailability through shear stress–induced eNOS activation, prostacyclin release, and neuronal NOS upregulation. Green et al. (2004) demonstrated that exercise training produces sustained improvements in endothelial function persisting for weeks.

The Lyon Diet Heart Study: Proof of Bypass

De Lorgeril et al. (Circulation, 1999): 605 post-MI patients. Mediterranean diet achieved a 70% reduction in cardiac death and non-fatal heart attacks. LDL levels in the two groups were identical. Seventy percent reduction. Zero LDL change. No statin trial has ever achieved this.

The Therapeutic Implication

Instead of lowering lipid particles, the goal is to restore NO through every available pathway: dietary nitrate from whole foods, protection of oral bacteria, regular sun exposure, daily aerobic exercise, L-citrulline supplementation, BH4 support through 5-MTHF and vitamin C, and polyphenol-rich foods. These interventions cost pennies compared to PCSK9 inhibitors (\$14,000/year).

The Bridge to the Virtuous Cycle

But the bypass pathways tell only half the story. Part XII establishes that we can restore NO even when eNOS is uncoupled. What the emerging evidence now reveals is something more profound: nitric oxide does not merely protect the wall from risk factors — it actively fights back against the risk factors themselves. The relationship between NO and risk factors is not one-directional. It is a two-way street. And that discovery changes everything.

— — —

Part XIII: The Virtuous Cycle — Nitric Oxide Ameliorates the Risk Factors

The Bidirectional Discovery

Parts I through XII establish a clear directional mechanism: risk factors generate superoxide, uncouple eNOS, deplete NO, and damage the arterial wall. The arrow runs from risk factors to wall damage.

But the arrow also runs the other way.

Emerging evidence from twelve peer-reviewed studies demonstrates that nitric oxide actively ameliorates and reverses the very risk factors that destroy it. Good metabolic health reduces eNOS uncoupling superoxide at one end AND inhibits lipoprotein retention at the other:

■ Risk Factors → ■ Superoxide → eNOS uncoupling / peroxynitrite loop → ■ NO → ■ PDGF + TGF- β → ■ Proteoglycan GAG chain length → ■ LDL binding → LIPOPROTEIN RETENTION

When NO is restored — through the bypass pathways, through risk factor reduction, or through targeted supplementation — the cascade reverses. NO suppresses PDGF and TGF- β . GAG chain elongation stops. Lipoprotein retention falls. The wall heals. This creates a **virtuous cycle** — and we have an additional **free kick**: a tool that works even while the original risk factors persist.

The Evidence: Twelve Studies

Study 1: Dietary Nitrate Reverses Arterial Damage — While Still on a Damaging Diet

Dietary inorganic nitrate supplementation was added to a high-fat, high-fructose (HFHF) diet. Result: carotid intima-media thickness changes were ameliorated despite continued consumption of the HFHF diet. The animals never stopped eating the damaging diet. The nitrate overrode the damage. This is not prevention. This is reversal in the face of ongoing insult.

Study 2: Ketone Bodies Negate Smoking Damage — and Reverse IMT While Still Smoking

β -hydroxybutyrate (BHB), a ketone body, completely negated the deleterious effects of cigarette smoking on eNOS function. BHB restored full eNOS coupling — and reversed IMT changes — in subjects who were still smoking. Smoking is ranked by Förstermann and Münzel as the single most potent driver of eNOS uncoupling. Yet restoring eNOS function through BHB reversed existing damage without smoking cessation. The mechanism: BHB reduces VCAM-1 expression and directly restores eNOS levels, breaking the peroxynitrite loop.

Study 3: Dietary Nitrate Reverses Metabolic Syndrome in eNOS-Deficient Mice

Carlström et al. (PNAS, 2010) demonstrated that dietary inorganic nitrate reverses features of metabolic syndrome in mice that completely lack eNOS. These mice develop metabolic syndrome — insulin resistance, elevated blood pressure, dyslipidemia. Dietary nitrate, working through the bypass pathway, reversed these

abnormalities. Even total absence of eNOS does not preclude metabolic rescue if NO is provided through an alternative route.

Study 4: The Anti-Obesogenic Role of eNOS

Sansbury et al. (2015) demonstrated that mice overexpressing eNOS show resistance to white adipose tissue accumulation on a high-fat diet, higher metabolic rate, resistance to diet-induced hyperinsulinemia, and remarkably lower plasma levels of free fatty acids and triglycerides. NO protects the wall AND prevents the metabolic conditions that attack the wall — the virtuous cycle at the whole-body level.

Study 5: Nitrate Outperforms Metformin for Cardiovascular Protection

A head-to-head comparison: both nitrate and metformin improved insulin and glucose homeostasis, but only nitrate had favorable effects on cardiovascular function and hepatic steatosis. Metformin — the most prescribed diabetes drug on Earth — matched nitrate for metabolic improvement but fell short on cardiovascular protection.

Study 6: Dietary Nitrate Prevents In-Stent Restenosis and Reduces MACE

In stented patients, dietary inorganic nitrate prevented in-stent restenosis and significantly reduced MACE rates at one and two years. SBP was reduced by 12.06 mmHg at six months. A food intervention producing MACE reduction in stented patients.

Study 7: Dietary Nitrite Reverses Hypercholesterolemic Microvascular Inflammation

Nitrite in drinking water inhibited leukocyte adhesion and emigration in hypercholesterolemic models — the very first steps in the inflammatory cascade that leads to plaque formation. Even in a hypercholesterolemic environment, NO prevents the wall from initiating the immune response that leads to atherosclerosis.

Study 8: Inorganic Nitrate Stabilizes Atherosclerotic Plaque

The anti-inflammatory actions of inorganic nitrate directly stabilize atherosclerotic plaques — reducing macrophage infiltration, suppressing inflammatory signaling, and promoting a stable plaque phenotype. The plaques that kill are the inflamed ones. NO calms them.

Study 9: NO Donor Reduces Myocardial Infarction

Molsidomine, a nitric oxide donor drug, favored features of plaque stability and reduced myocardial infarction. Instead of lowering LDL, develop drugs that provide NO — which the wall desperately needs.

Study 10: eNOS Is the Bridge Between Metabolic Syndrome and Cardiovascular Disease

A comprehensive review confirms that a reduction in endothelium-derived NO serves as the key mechanistic link between metabolic disorders and cardiovascular risk. eNOS is not merely damaged by metabolic syndrome — it is the molecular bridge through which metabolic disease becomes cardiovascular disease. Fix the wall, break the bridge.

Study 11: Sustained Blood Pressure Reduction from Dietary Nitrate (RCT)

A phase 2, double-blind, randomized, placebo-controlled trial demonstrated that dietary nitrate provides sustained blood pressure lowering in hypertensive patients. Gold-standard evidence that a dietary NO source achieves what blood pressure medications achieve — through the wall.

Study 12: Women Produce 2× More eNOS — The Molecular Basis of the Paradox

Cattaneo et al. (Scientific Reports, 2017) demonstrated that both eNOS gene expression and protein expression are approximately 2-fold higher in female endothelial cells compared to male. The sex with more eNOS has less heart disease. Not less cholesterol. More eNOS. Perhaps the most elegant single confirmation of the wall theory.

The Implication: A New Therapeutic Paradigm

Even while risk factors persist, restoring NO can reverse arterial damage. Even without eNOS, alternative pathways can rescue metabolic dysfunction. NO actively resists obesity and insulin resistance — the #1 root cause. NO outperforms leading pharmaceuticals for cardiovascular protection. NO reduces hard clinical endpoints (MACE). NO counteracts the inflammatory effects of elevated cholesterol. NO stabilizes the plaques that kill. And the sex with more eNOS has less heart disease.

The wall theory is not only an explanation of disease. It is a roadmap for intervention. Restore the wall. Restore NO. The risk factors weaken. The virtuous cycle begins. And you don't need a prescription — you need beets, leafy greens, sunshine, exercise, and the wisdom to stop targeting the wrong molecule.

— — —

Part XIV: Genetics and the Loaded Wall

Genetic variants do not cause heart disease by raising cholesterol. They cause heart disease by weakening the wall's defense systems — by loading the wall with vulnerabilities that the twelve root causes then exploit.

NOS3 (rs1799983, G894T — Glu298Asp)

This variant in the eNOS gene reduces enzyme activity and NO bioavailability. Carriers have a genetically narrower margin of error and benefit disproportionately from NO-supporting interventions.

MTHFR C677T (rs1801133)

Reduces MTHFR enzyme activity by ~30% (heterozygous) to ~70% (homozygous), impairing BH4 recycling and raising homocysteine. Carriers should supplement with methylfolate (5-MTHF), not folic acid.

SOD2 (rs4880, Ala16Val)

Affects superoxide dismutase efficiency in mitochondria, potentially reducing superoxide clearance and increasing vulnerability to the peroxynitrite cascade.

GSTP1 (rs1695, Ile105Val)

Reduces glutathione S-transferase activity, impairing detoxification of oxidative damage products including 4-HNE from oxidized omega-6 fatty acids.

9p21 (rs10757278)

The strongest genetic risk locus for CAD. Risk allele (GG) approximately doubles MI risk — completely independent of LDL, blood pressure, diabetes, and smoking. The mechanism operates through the arterial wall's inflammatory environment, not lipid mediation.

APOE ε4

Increases susceptibility of LDL particles to oxidative modification — meaning wall defense systems are more critical, not less. These individuals benefit most from aggressive antioxidant support and wall-protective interventions.

LPA Gene Variants

Determine genetically fixed Lp(a) levels. As the HORIZON trial demonstrated, lowering the particle does not reduce events. Management must focus on the wall, not the particle.

The Genetic Loading Concept

The twelve root causes are the bullets. The genetic variants are the holes in the armor. Remove the bullets and the armor holds — even with the holes. The standard of care measures none of these variants routinely. It measures LDL.

— — —

Part XV: The Ten Tests That Actually Matter

The standard lipid panel tells you nothing about the condition of the arterial wall. These ten tests constitute a wall-centric diagnostic framework.

Test 1: Fasting Insulin — Optimal: $< 5 \mu\text{IU/mL}$

The earliest and most sensitive marker of insulin resistance. Insulin levels rise years to decades before fasting glucose becomes abnormal.

Test 2: HOMA-IR — Optimal: < 1.0

Calculated from fasting insulin and glucose: $(\text{Insulin} \times \text{Glucose}) / 405$. Below 1.0 indicates excellent insulin sensitivity.

Test 3: Triglyceride-to-HDL Ratio — Optimal: < 1.0

The single best lipid-derived marker of metabolic health. Below 1.0 indicates large, buoyant LDL particles (Pattern A). Above 2.0 indicates small, dense LDL (Pattern B).

Test 4: hs-CRP — Optimal: $< 1.0 \text{ mg/L}$

The most validated marker of systemic inflammation. CANTOS proved inflammation independently drives events. JUPITER showed statin benefit tracked CRP, not LDL.

Test 5: HbA1c — Optimal: $< 5.2\%$

Time-averaged glucose exposure over 90 days. Glycation damage already occurs at levels considered "normal" by standard criteria.

Test 6: ApoB

Total atherogenic particle count. Included as context, not primary target. When all wall markers are optimal and ApoB is extremely high, the wall's defenses may be tested at scale.

Test 7: Lp(a)

Approximately 90% genetically determined. Measured once for risk stratification. HORIZON proved lowering the particle doesn't reduce events — but elevated Lp(a) informs intensity of wall-protective interventions.

Test 8: Homocysteine — Optimal: $< 9 \mu\text{mol/L}$

Directly damages the endothelium, increases superoxide, reduces NO, and elevates ADMA. Particularly important in MTHFR variant carriers.

Test 9: Fasting Glucose — Optimal: $< 86 \text{ mg/dL}$

A complement to insulin, HOMA-IR, and HbA1c. A fasting glucose of 95 with a fasting insulin of 15 represents significant insulin resistance despite both being "normal."

Test 10: Full Thyroid Panel

TSH, Free T3, Free T4, Reverse T3, thyroid antibodies (TPO, TG). Thyroid function directly regulates eNOS expression. Standard practice measuring only TSH misses subclinical dysfunction.

Five of these tests measure insulin resistance because it is the single most prevalent and destructive root cause, and the most amenable to intervention. Not one is routinely performed in standard cardiovascular risk assessment. The standard lipid panel measures the passengers. These ten tests measure the wall.

— — —

Conclusion: The Wall Was Always the Variable

This paper has assembled evidence from three Nobel Prize–winning discoveries, sixty clinical trials, seven failed drug programs, five clinical paradoxes, twenty-one years of prospective hazard ratio data, twelve studies demonstrating the bidirectional relationship between nitric oxide and risk factors, a 14.9-million-person Korean cohort confirming the U-shaped mortality curve of LDL, and over fifty-seven peer-reviewed publications spanning six decades. The evidence converges on a single conclusion:

Atherosclerotic cardiovascular disease is a disease of the arterial wall, not of circulating lipid particles.

- 75% of heart attack patients have normal LDL (Sachdeva, 2009)
- 60 trials, 323,950 patients: near-zero mortality benefit from LDL reduction
- Seven drug trials hit their lipid targets and failed clinically
- The HORIZON trial lowered Lp(a) 77% and failed to reduce events (2026)
- CANTOS proved inflammation reduction alone reduces events (Ridker, 2017)
- The Lyon Diet Heart Study achieved 70% event reduction with zero LDL change
- Hazard ratios rank LDL at 1.4x while diabetes ranks at 10.0x (Dugani, 2021)
- Statins work through eNOS upregulation, not LDL lowering (Laufs, 1998)
- Brown and Goldstein proved native LDL does not form foam cells (Nobel, 1985)
- Three CETP inhibitors raised HDL spectacularly and achieved nothing
- Minnesota Coronary Experiment: lowered cholesterol, more died (Ramsden, 2016)
- Framingham Directors: each 1% cholesterol drop = 11% mortality increase
- 14.9 million Koreans not on statins: U-shaped LDL mortality curve — both extremes cost lives
- NO reverses arterial damage even while risk factors persist
- NO reverses metabolic syndrome, resists obesity, stabilizes plaque
- Dietary nitrate reduces MACE and outperforms metformin for CV protection
- Women produce 2× more eNOS and have less heart disease until menopause

The Path Forward

Diagnosis must shift from particle counting to wall assessment. The ten tests described in this paper should replace the standard lipid panel as the primary cardiovascular risk assessment.

Treatment must shift from particle suppression to wall repair. The twelve root causes provide twelve actionable intervention targets. The NO bypass pathways provide alternative routes to restore nitric oxide. And the virtuous cycle shows that restoring NO actively fights back against the risk factors themselves.

Research must shift from lipid targets to wall targets. Future drug development should target eNOS recoupling, BH4 restoration, glycocalyx repair, superoxide neutralization, and ADMA reduction.

The Stakes

Cardiovascular disease kills 17.9 million people per year worldwide — more than cancer, more than infectious disease, more than any other cause. For fifty years, the dominant strategy has been to lower LDL cholesterol. For fifty years, cardiovascular disease has remained the #1 killer.

The wall was always the variable.

The evidence has been published. The Nobel Prizes have been awarded. The paradoxes have been documented. The failed trials have reported their results. The hazard ratios have been calculated. The virtuous cycle has been demonstrated.

What remains is the will to look.

— — —

Acknowledgments

This book would not exist in its current form without Peter Anderson.

Peter is the independent researcher who identified the bidirectional relationship between nitric oxide and the risk factors — what this book calls the virtuous cycle. While the published literature on eNOS uncoupling and superoxide-driven atherosclerosis has existed for decades, it was Peter who assembled the twelve studies demonstrating that nitric oxide does not merely respond to risk factors but actively ameliorates them. That insight — that the cascade runs in both directions — transformed a theoretical framework into a practical one.

Part XIII of this book, *The Virtuous Cycle*, is built almost entirely on research Peter identified and shared. The carotid IMT reversals while still smoking. The metabolic syndrome reversal in eNOS-deficient mice. The head-to-head comparison with metformin. The in-stent restenosis prevention. The plaque stabilization evidence. Every one of those studies came from Peter's relentless digging through the vascular biology literature.

Peter had a stent placed in his mid-fifties after exercising too hard with a strong family history of atherosclerosis. Like many of us, that event changed the direction of his life. He pivoted from clinical practice to vascular biology research with a singular conviction: that coronary artery disease can be stopped — not managed, stopped.

He was right. The evidence was always there. Peter found it.

Thank you, Peter.

— — —

References

1. Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? *BMJ*. 2013;347:f6123.
2. AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med*. 2011;365(24):2255-2267.
3. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. *JAMA*. 1987;257(16):2176-2180.
4. Arabadjian M, Engel SM, Engel L. Prevalence of optimal metabolic health in American adults. *Metab Syndr Relat Disord*. 2018;16(5):218-222.
5. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. *N Engl J Med*. 2007;357(21):2109-2122.
6. Böger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. *Pharmacol Ther*. 2006;114(3):276-294.
7. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. *Science*. 1986;232(4746):34-47.
8. Calvin AD, Covassin N, Kremers WK, et al. Experimental sleep restriction causes endothelial dysfunction in healthy humans. *Hypertension*. 2014;64(4):e42.
9. Carlström M, Persson AEG, Larsson E, et al. Dietary nitrate attenuates oxidative stress, prevents cardiac and renal injuries, and reduces blood pressure in salt-induced hypertension. *PNAS*. 2010;107(41):17716-17720.
10. CTT Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol. *Lancet*. 2010;376(9753):1670-1681.
11. Crabtree MJ, Channon KM. Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease. *Free Radic Biol Med*. 2011;50(4):463-473.
12. De Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. *Circulation*. 1999;99(6):779-785.
13. Dimsdale JE. Psychological stress and cardiovascular disease. *J Am Coll Cardiol*. 2008;51(13):1237-1246.
14. Dugani SB, Moorthy MV, Li C, et al. Association of lipid, inflammatory, and metabolic biomarkers with age at onset of first total cardiovascular events in women. *JAMA Cardiol*. 2021;6(5):505-515.
15. Erviti J, Wright J, Bassett K, et al. Restoring mortality data in the FOURIER cardiovascular outcomes trial. *BMJ Open*. 2022;12(6):e060172.
16. Felton CV, Crook D, Davies MJ, Oliver MF. Dietary polyunsaturated fatty acids and composition of human aortic plaques. *Lancet*. 1994;344(8931):1195-1196.
17. Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease. *Circulation*. 2006;113(13):1708-1714.
18. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature*. 1980;288(5789):373-376.
19. Green DJ, Maiorana A, O'Driscoll G, Taylor R. Effect of exercise training on endothelium-derived nitric oxide function in humans. *Exerc Sport Sci Rev*. 2004;32(3):99-106.
20. Harrison DG, Gongora MC. Oxidative stress and hypertension. *Free Radic Biol Med*. 2009;46(5):543-553.
21. Heller R, Unbehauen A, Schellenberg B, et al. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. *J Biol Chem*. 2001;276(1):40-47.
22. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. *N Engl J Med*. 2014;371(3):203-212.
23. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. *N Engl J Med*. 2017;377(2):111-121.
24. Kapil V, Haydar SMA, Pearl V, et al. Physiological role for nitrate-reducing oral bacteria in blood pressure control. *Free Radic Biol Med*. 2013;55:93-100.

25. Kaplan H, Thompson RC, Trumble BC, et al. Coronary atherosclerosis in indigenous South American Tsimane. *Lancet*. 2017;389(10080):1730-1739.
26. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. *N Engl J Med*. 2008;358(14):1431-1443.
27. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. *Circulation*. 1998;97(12):1129-1135.
28. Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. *JAMA*. 2017;317(12):1256-1263.
29. Liu D, Fernandez BO, Hamilton A, et al. UVA irradiation of human skin vasodilates arterial vasculature and lowers blood pressure independently of nitric oxide synthase. *J Invest Dermatol*. 2014;134(7):1839-1846.
30. Nieuwdorp M, van Haeften TW, Gouverneur MCLG, et al. Loss of endothelial glycocalyx during acute hyperglycemia. *Diabetes*. 2006;55(2):480-486.
31. Nishimura T, Yokoyama T, Kasai N, et al. Functional and structural properties of apolipoprotein A-I Milano. *J Lipid Res*. 2005;46(4):743-754.
32. Opländer C, Volkmar CM, Paunel-Görgülü A, et al. Whole body UVA irradiation lowers systemic blood pressure by release of nitric oxide. *Free Radic Biol Med*. 2009;47(4):e17.
33. Ramsden CE, Zamora D, Majchrzak-Hong S, et al. Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment. *BMJ*. 2016;353:i1246.
34. Razvi S, Shakoor A, Vanderpump M, et al. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease. *JAMA*. 2012;167(14):1526-1532.
35. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). *N Engl J Med*. 2008;359(21):2195-2207.
36. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). *N Engl J Med*. 2017;377(12):1119-1131.
37. Ross R. Atherosclerosis — an inflammatory disease. *N Engl J Med*. 1999;340(2):115-126.
38. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease. *Am Heart J*. 2009;157(1):111-117.e2.
39. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome (Dal-OUTCOMES). *N Engl J Med*. 2012;367(22):2089-2099.
40. Seals DR, Jablonski KL, Donato AJ. Aging and vascular endothelial function in humans. *Clin Sci*. 2011;120(9):357-375.
41. Tang WHW, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. *N Engl J Med*. 2013;368(17):1575-1584.
42. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylaminohydrolase pathway. *Arterioscler Thromb Vasc Biol*. 2004;24(6):1023-1030.
43. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature*. 2011;472(7341):57-63.
44. HORIZON trial. Pelacarsen for lowering lipoprotein(a) and cardiovascular events. Results presented September 4, 2026. Primary endpoint not met.
45. Dietary inorganic nitrate ameliorates carotid intima-media changes in a high-fat, high-fructose diet model. *Anatomy Journal of Africa*.
46. Effects of ketone body β -hydroxybutyrate on eNOS levels and VCAM-1 in smoking models. Repository UNAIR.
47. Carlström M, Larsen FJ, Nyström T, et al. Dietary inorganic nitrate reverses features of metabolic syndrome in eNOS-deficient mice. *PNAS*. 2010. DOI: 10.1073/pnas.1008872107.
48. Sansbury BE, Cummins TD, Tang Y, et al. Anti-obesogenic role of endothelial nitric oxide synthase. *PMC*. 2015.
49. Head-to-head comparison of inorganic nitrate and metformin in cardiometabolic disease. *Nitric Oxide*.
50. Dietary nitrate supplementation prevents in-stent restenosis and reduces MACE. *EClinicalMedicine*.

51. Stokes KY, Duber BJ, Granger DN. Dietary nitrite prevents hypercholesterolemic microvascular inflammation. *Am J Physiol Heart Circ Physiol*.
52. Jantzi J, et al. Antiinflammatory actions of inorganic nitrate stabilize the atherosclerotic plaque. *PMC*. 2017.
53. Roth L, et al. Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability. *Atherosclerosis*. 2019.
54. Huang PL. eNOS, metabolic syndrome and cardiovascular disease. *Trends Endocrinol Metab*. 2009.
55. Kapil V, Khambata RS, Robertson A, et al. Dietary nitrate provides sustained blood pressure lowering in hypertensive patients. *Hypertension*. 2015;65(2):320-327.
56. Cattaneo MG, Vanetti C, Strettoi E, et al. Sex-specific eNOS activity and function in human endothelial cells. *Sci Rep*. 2017;7(1):9612.
57. Korean nationwide cohort study. LDL cholesterol and cardiovascular mortality in 14.9 million statin-free adults followed for nearly 9 years. U-shaped mortality curve; optimal CV death risk at LDL 90–149 mg/dL.

57

Citations

15

Sections

3

Nobel Prizes

12

Root Causes

It was never the particle. It was always the wall.

Read the science. Question the paradigm.

neoroot.ai

© 2026 HealthTruth Inc. All rights reserved.
Every claim cited. Every mechanism published.